Laboratory technology firm BioGrad has inaugurated a new lab in Yorkshire as part of an ambitious £3 million investment, continuing its national expansion strategy.
Liverpool-based BioGrad has unveiled its latest research and teaching site in York, a move anticipated to place the company at the forefront of science, healthcare, regenerative medicine, and clinical research over the next three years. The firm’s strategic plans include announcing a nationwide clinical trial led by the York team in early 2025.
Since 2022, BioGrad has progressively established labs in Birmingham, Newcastle, and London. Additionally, the company has developed its headquarters and purpose-built clinical research centre at Wavertree Technology Park in Liverpool. The firm, which now employs approximately 150 people, recently saw its educational arm become the first North West company to secure investment from the £660 million Northern Powerhouse Investment Fund II.
Dr Natalie Kenny, CEO at BioGrad, detailed the motivations behind the expansion into York, noting the critical support received from local authorities and the region’s robust strengths, including its NHS Trust and universities. “Our expansion into York represents an exciting new era for BioGrad as we extend our reach across the UK,” Kenny remarked. She expressed gratitude towards Sophie Hartley, sector development relationship manager at York and North Yorkshire Combined Authority, and Christine Hogan, inward investment manager at City of York Council, for their instrumental support. “We take immense pride in our UK-wide presence and eagerly anticipate furthering our efforts to create new jobs and opportunities across the region,” she added.
David Skaith, Mayor of York and North Yorkshire, highlighted the significance of BioGrad’s investment in the region. “It is great to see laboratory testing specialist, BioGrad, move into York with an investment of more than £3 million over the next three years,” Skaith stated. He emphasised that the new research and teaching site will create high-quality, skilled jobs in a high-growth sector. BioGrad’s arrival aligns with the region’s demographic advantages and its array of research centres and world-leading universities, positioning it as a key player in global healthcare.
BioGrad’s expansion into Yorkshire marks a significant development in the firm’s growth trajectory, promising substantial contributions to science and healthcare through new research, job creation, and regional development.
